IFN-β is required for efficient adaptive immunity against VV in vivo. (A) Maturation of splenic CD11c+ DCs. Wild-type 129/Sv (WT) or IFN-αβR−/− mice were administered 1 × 107 pfu VV intravenously, and splenocytes were harvested 24 hours later, stained with anti-CD11c and anti-CD86 or an isotype control antibody (isotype), and analyzed for CD86 expression by FACS based on isotype control antibody staining on respective CD11c+ cells. The percentages of CD11c+ DCs expressing CD86 are indicated. (B) VV-specific T-cell activation. Seven days after VV infection, CD5+ T cells purified from splenocytes were restimulated with VV at an MOI of 0.5, 0.1, or 0.02 in the presence of corresponding naive irradiated splenocytes. Proliferation of virus-specific T cells was analyzed by 3H-thymidine incorporation. Data reflect the mean plus or minus SD of the stimulation index, calculated by dividing 3H counts in cpm in the presence of viral stimulation by those in the absence of stimulation, as a function of different virus doses. T cells from uninfected 129/Sv mice were used as control (control). (C) Activation of VV-specific effector CD8 T cells. Seven days after infection, splenocytes were stimulated with anti-CD3 and anti-CD28 for 4 hours and assayed for intracellular IFN-γ secretion by CD8 T cells. Events were gated on total lymphocytes. The percentages of IFN-γ–producing CD8 T cells among total lymphocytes are indicated.